Most state Medicaid programs are rejecting a federal proposal from the Trump administration designed to expand access to high-priced weight-loss drugs. Despite the offer of negotiated price discounts on GLP-1 medications like Wegovy and Zepbound, state officials across the country express significant concern regarding the long-term financial burden the policy would place on their respective budgets.
The Disconnect Between Federal Policy and State Reality
President Donald Trump announced a model last year intended to lower costs and broaden access to weight-loss treatments for low-income patients. The plan hinges on direct negotiations between the Centers for Medicare and Medicaid Services and drug manufacturers. The goal is to lower prices for states without shifting the financial burden entirely to taxpayers. Still, the response from state leaders has been cool.
Only Indiana has committed to the program as of late August 2026. Twenty-nine state Medicaid programs have explicitly opted out, while another 14 states failed to provide a response to inquiries regarding their participation. This widespread rejection signals a tension between federal health policy objectives and the stark fiscal realities faced by state health departments.
Financial Constraints and Legislative Hurdles
State agencies are operating under tight fiscal constraints, often compounded by broader federal funding cuts. Officials in states such as Florida, Oregon, and Hawaii describe the program as too expensive to justify, even with the promised manufacturer discounts. They argue that the upfront cost remains prohibitive. Legislators in states like North Dakota have already signaled their unwillingness to authorize the necessary funding for such an expansion.
Louisiana Medicaid Director Seth Gold expressed a desire to improve health outcomes but noted the high risk of beginning a coverage program that a state cannot maintain. California, for example, recently withdrew coverage for weight-loss drugs after projecting that expenditures would hit $800 million by 2028-29. This trend of states retreating from coverage plans creates a precarious situation for Medicaid patients who have relied on these drugs for weight management and associated health improvements.
Future Implications for State Coverage
Manufacturers like Novo Nordisk and Eli Lilly are actively pressuring states to look past initial costs. They contend that the drugs reduce the incidence of expensive conditions such as cardiovascular disease and liver failure, which are significant drivers of Medicaid spending. While the federal government remains optimistic about the model, state officials are wary of the lack of clarity regarding long-term cost savings.
State policymakers are watching Indiana to determine how the model performs in practice over the coming year. Meanwhile, programs like the TrumpRx discount platform provide an alternative route for patients, though prices remain unaffordable for many. As Medicaid spending on these specific drugs ballooned to $9 billion in 2024, the debate over how to manage both access and costs is unlikely to resolve soon. States will continue to prioritize budgetary sustainability as they evaluate whether to adopt federal health models.